NHLBI Asthma Phenotypes-Lockey - World Allergy Organization

More documents

Recommendations

Info

Early Phase Reaction (EPR) Occurs Within Minutes of Allergen Exposure in Sensitized Subjects Allergen Mast cell Degranulation Neosynthesis Preformed mediators – Histamine – Proteases Newly generated mediators – Cysteinyl leukotrienes – Prostaglandins – PAF – Bradykinin – Interleukins – TNF-α – GM-CSF Blood vessels, nerves, mucus glands, smooth muscle Symptoms of <strong>Asthma</strong> Wheezing Coughing Shortness of Breath Tight Chest 11/15/00 SLIDE 9
Current Standard Treatments (based on NIH guidelines) • Short and long-acting inhaled beta-2 agonists • Inhaled corticosteroids • Leukotriene modifiers • Theophylline • Cromolyn and Nedocromil
Page 1 and 2:
Defining Phenotypes: Expanding Our
Page 3 and 4:
Asthma Phenotype Task Force NHLBI,
Page 5 and 6:
Asthma Phenotype Task Force Goal Co
Page 7 and 8:
Asthma Phenotypes • Define 9 phen
Page 9 and 10:
Asthma Phenotypes • Define 9 phen
Page 11 and 12:
Allergic Proposed Definition • Se
Page 13 and 14:
Allergic Asthma: Clinical Informati
Page 15 and 16:
Non-Allergic Asthma Background •
Page 17 and 18:
Non-Allergic Asthma: Demographic an
Page 19 and 20:
Aspirin-Exacerbated Respiratory Dis
Page 21 and 22:
AERD Task Force Proposed Definition
Page 23 and 24:
AERD Genetics 1. Familial cases rep
Page 25 and 26:
AERD Clinical Features (cont’d) 4
Page 27 and 28:
Infection-Induced Asthma: Definitio
Page 29 and 30:
Infection-Induced Asthma: Histopath
Page 31 and 32:
Background Exercise-Induced Asthma
Page 33 and 34:
Exercise-Induced Bronchospasm: Defi
Page 35 and 36: Clinical Characteristics • EIB oc
Page 37 and 38: Background on Pre-Asthma Wheezing i
Page 39 and 40: Pre-Asthma Wheezing in Infants and
Page 41 and 42: Pre-Asthma Wheezing in Infants and
Page 43 and 44: Asthma Phenotypes - Clinical presen
Page 45 and 46: Background Exacerbation Prone Asthm
Page 47 and 48: Definition Exacerbation Prone Asthm
Page 49 and 50: Background Irreversible Airflow Lim
Page 51 and 52: Irreversible Airflow Limitation in
Page 53 and 54: Background Eosinophilic Asthma: Ass
Page 55 and 56: Asthma Phenotypes - Clinical presen
Page 57 and 58: Definition Neutrophilic Asthma Intr
Page 59 and 60: Asthma Phenotypes Task Force Nation
Page 61 and 62: Summary: Asthma Phenotype Definitio
Page 63 and 64: Haldar P et al. Am J Respir Crit Ca
Page 66: Asthma: Challenges in Treating a He
Page 69 and 70: Asthma Is Prevalent: Significant Mo
Page 71 and 72: Asthma Phenotype Task Force NHLBI,
Page 73 and 74: Asthma Phenotype Task Force Goal Co
Page 75 and 76: Asthma Phenotypes • Define 9 phen
Page 77 and 78: Co-Morbid Conditions which Complica
Page 79 and 80: 6. Osteopenia and Osteoporosis 7. P
Page 82 and 83: Asthma • Historical Definition: -
Page 84 and 85: Airway Inflammation • Also caused
Page 88 and 89: Short and long-acting beta-2 agonis
Page 90 and 91: Short and long-acting beta-2 agonis
Page 92 and 93: Inhaled Corticosteroids (ICS)
Page 94 and 95: Inhaled Corticosteroids (ICS) • S
Page 96 and 97: GC Resistance in Asthma: • Defini
Page 98 and 99: Leukotriene Modifiers • Strengths
Page 100 and 101: Theophylline • Limitations: - Inf
Page 102 and 103: Omalizumab • FDA-approved for pat
Page 104 and 105: Omalizumab (Cochrane Database) •
Page 106 and 107: Allergen Immunotherapy - Allergen i
Page 108 and 109: Asthma Assessment and Monitoring: K
Page 110: Assessing Asthma Severity: Risk Dom
Page 114: Categories of Evidence Used to Supp
Page 117: Estimated Comparative Daily Dosages
Page 128 and 129: Conclusions • Severity, control,
show all

NHLBI Asthma Phenotypes-Lockey - World Allergy Organization

Create successful ePaper yourself

Delete template?

Save as template?